Relay Therapeutics Inc share price logo

Relay Therapeutics Inc

NASDAQ: RLAY

Mid Cap

$13.57

-0.52

(-3.69%)

Live

as on

Relay Therapeutics Inc Stock Performance

as on June 11, 2026 at 5:26 am IST

  • Day's Low

    Day's High

    $13.47
    $14.56
    downward going graph

    0.74%

    Downside

    7.30%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.98
    $17.47
    downward going graph

    78.04%

    Downside

    28.74%

    Upside

    downward going graph

Relay Therapeutics Inc share price movements today

Previous Close
$14.09
Open
$13.91
Volume
1.8M
Day's Low - High
$13.47 - $14.56
52 Week Low - High
$2.98 - $17.47

Relay Therapeutics Inc Historical Returns

1 Month Return
+ 10.42 %
3 Month Return
+ 31.81 %
1 Year Return
+ 303.72 %
3 Year Return
+ 31.07 %
5 Year Return
-58.86 %

Relay Therapeutics Inc Stock Fundamentals & Key Indicators

Check Relay Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.9B

EPS (TTM)

-1.5524

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-40.01%

Relay Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Relay Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$2.9B-58.86%NA0.00%NA
BUY$39.0B82.34%73.5912.55%NA
BUY$112.4B105.64%26.3235.51%NA
BUY$64.1B15.81%14.9329.65%0.5599999999999999%

Stock Returns calculator for Relay Therapeutics Inc Stock including INR - Dollar returns

The Relay Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Relay Therapeutics Inc investment value today

Current value as on today

₹4,45,025

Returns

₹3,45,025

(+345.03%)

Returns from Relay Therapeutics Inc Stock

₹2,88,825 (+288.83%)

Dollar Impact

₹56,200 (+56.2%)

Analyst Recommendation on Relay Therapeutics Inc Stock

Based on 18 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 18 analysts, 83.33% of analysts recommend a 'BUY' rating for Relay Therapeutics Inc. Average target price of $24.25

Relay Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Relay Therapeutics Inc.

What analysts predicted

44.04%UPSIDE

Target Price

$24.25

Current Price

$13.57

Analyzed by

18 Analysts

Target

$24.25

Relay Therapeutics Inc target price $24.25, a slight upside of 44.04% compared to current price of $13.57. According to 18 analysts rating.

Indian Investors' Interest in Relay Therapeutics Inc Stock

Search interest for Relay Therapeutics Inc Stock has increased by 24% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:24% versus previous 30 day period

Relay Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
10
-
-
-
7
0
-
7
3
Gross Profit
0
10
-1
-1
-7
7
0
0
6
2
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-83
-81
-92
-88
-76
-77
-70
-74
-54
-73
Net Profit Margin
8349500.00%
-813.30%
0.00%
0.00%
0.00%
-1003.58%
-10395.13%
0.00%
-784.14%
-2443.03%

Relay Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
82
3
1
25
10
15
Gross Profit
-2
-2
79
3
1
25
10
11
Operating Income
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
Net Income
-48
-66
-52
-363
-290
-341
-337
-276
Net Profit Margin
0.00%
0.00%
-63.41%
-12012.94%
-21036.13%
-1338.66%
-3374.72%
-1800.58%

Global Institutional Holdings in Relay Therapeutics Inc

Funds
Holdings
Alphabet Inc
0.83%
TCG Crossover Management, LLC
1.96%
Geode Capital Management, LLC
1.61%
Balyasny Asset Management LLC
1.39%
COMMODORE CAPITAL LP
7.8%

Relay Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 03 December

    Wed, 07:17 PM

    -

    Commodore Capital increased its stake in Relay Therapeutics by 3.65 million shares, raising its position to 17 million shares.

    Wed, 07:26 PM

    -

    Relay Therapeutics' Director sold $300,000 worth of shares, primarily due to company policy on stock compensation.

Insights on Relay Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, RLAY has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, RLAY stock has moved up by 85.6%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, RLAY has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 7.0M → 3.0M (in $), with an average decrease of 57.1% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -54.89M → -73.29M (in $), with an average decrease of 33.5% per quarter

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
OrganisationRelay Therapeutics Inc
Headquarters60 Hampshire Street, Cambridge, MA, United States, 02139
IndustryBiotechnology
CEODr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
E-voting on sharesClick here to vote

Key Management of Relay Therapeutics Inc

Name

Title

Ms. Soo-Yeun Lim J.D.

Senior VP & General Counsel

Mr. Thomas Catinazzo

Chief Financial Officer

Ms. Dorothee Kern Ph.D.

Founder

Dr. David Elliot Shaw Ph.D.

Founder

Dr. Matthew P. Jacobson Ph.D.

Founder

Mr. Jim Watters Ph.D.

Chief Scientific Officer

Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

CEO, President & Director

Dr. Mark Murcko Ph.D.

Founder & Independent Director

Mr. Peter Rahmer

Chief Corporate Development Officer

Dr. Donald A. Bergstrom M.D., Ph.D.

President of Research & Development

FAQs

What is Relay Therapeutics Inc share price today?

Relay Therapeutics Inc share price today is $13.57 as on . Relay Therapeutics Inc share today touched a day high of $14.56 and a low of $13.47.

What is the 52 week high and 52 week low for Relay Therapeutics Inc share?

Relay Therapeutics Inc share touched a 52 week high of $17.47 on and a 52 week low of $2.98 on . Relay Therapeutics Inc stock price today i.e. is trending at $13.57,which is 22.32% down from its 52 week high and 355.37% up from its 52 week low.

What is Relay Therapeutics Inc's market capitalisation today?

Relay Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Relay Therapeutics Inc Stock (RLAY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Relay Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Relay Therapeutics Inc Shares that will get you 0.1105 shares as per Relay Therapeutics Inc share price of $13.57 per share as on June 10, 2026 at 11:56 pm IST.

What is the minimum amount required to buy Relay Therapeutics Inc Stock (RLAY) from India?

Indian investors can start investing in Relay Therapeutics Inc (RLAY) shares with as little as ₹95.34 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.40 in Relay Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Relay Therapeutics Inc share’s latest price of $13.57 as on June 10, 2026 at 11:56 pm IST, you will get 0.7369 shares of Relay Therapeutics Inc. Learn more about fractional shares .

What are the returns that Relay Therapeutics Inc has given to Indian investors in the last 5 years?

Relay Therapeutics Inc stock has given -58.86% share price returns and 21.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?